DermTech sponsors the San Diego Open; Tennis Pro Partner Brandon Nakashima to Raise Sun Safety Awareness
LA JOLLA, Calif .– (COMMERCIAL THREAD) – DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology through a non-invasive skin genomics platform, today announced the sponsorship of San Diego Open, an ATP 250, and a partnership with Brandon Nakashima, native of San Diego and tennis pro. Sponsorships further represent DermTech’s commitment to the San Diego community and its goal of raising awareness of the importance of sun protection and skin checks to aid in the early detection of melanoma.
The San Diego Open, held at the Barnes Tennis Center from September 27 to October 3, 2021, features a 28-player singles draw and a 16-team doubles draw. As a sponsor of the event, DermTech aims to help educate attendees and the San Diego community on the value of practicing sun protection and the importance of regular skin checks during the event in the open. iconic look.
“As a company with deep roots in the San Diego community, DermTech is honored to sponsor the San Diego Open and to launch an excellent partnership with Brandon Nakashima,” said John Dobak, MD, CEO of DermTech. “We look forward to participating in this fantastic tennis event and promoting the importance of sun protection and overall skin health.”
As a DermTech Ambassador and tennis pro who spends much of his time outdoors, Nakashima will highlight sun safety, draw attention to the critical need for skin checks and the DermTech Melanoma Test, the first non-invasive test that allows dermatologists to check an atypical mole painlessly and non-invasively for melanoma.
“My parents are frontline healthcare workers who have always emphasized the importance of taking care of my health, especially my skin,” said Brandon Nakashima. “As professional tennis players we spend a lot of time outside in the sun, and I am happy to be able to help spread awareness of DermTech, its DermTech Melanoma test and the need for sun protection.”
For more information on DermTech, please visit: www.dermtech.com.
DermTech is the leading dermatology genomics company creating a new category of medicine, precision dermatology, made possible by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatological care and to improve the lives of millions of people. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancer and develops products that assess inflammatory diseases and personalize drug treatments. For more information on DermTech, please visit the DermTech Investor Relations site at: www.dermtech.com.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. DermTech’s expectations, estimates and projections may differ from its actual results and, therefore, you should do not rely on these forward-looking statements as predictions of future events. Words such as “expect”, “estimate”, “project”, “budget”, “plan”, “anticipate”, “intend to”, “plan”, “can”, “will”, “Could”, “should,” “believe”, “predict”, “potential”, “continuing” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations regarding: (1) the timing and expected benefits of the renovation and the Company’s occupancy of the newly leased property, and (2) performance, benefits for patients, the profitability, commercialization and adoption of DermTech’s products and the resulting market opportunity. These forward-looking statements involve significant risks and uncertainties which could cause actual results to differ materially from expected results. Most of these factors are beyond DermTech’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be brought against DermTech; (2) the ability of DermTech to obtain additional financing to develop and market its products; (3) the existence of clinical guidelines favorable or unfavorable to DermTech testing; (4) reimbursement of DermTech tests by Medicare and private payers; (5) the ability of patients or healthcare providers to obtain sufficient coverage or reimbursement for DermTech products; (6) DermTech’s ability to grow, manage growth and retain key employees; (7) changes in applicable laws or regulations; (8) market uptake and demand for DermTech’s products and services as well as the possibility that DermTech may be adversely affected by other economic, business and / or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the “SEC”) , and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the above list of factors is not exclusive. You should not place undue reliance on forward-looking statements, which speak only as of the date they are posted. DermTech does not undertake or accept any obligation or commitment to publicly release updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in the events, conditions or circumstances upon which such statement is made. based.